![]() In May 2022, UNP further upped its quarterly dividend by 10%. The company hiked dividend twice in 2021. However, Union Pacific's efforts to reward its shareholders even in the current uncertain scenario please us. The same is likely to have been high in the December quarter as well. This phenomenon induced a 22% rise in the operating expenses in the first nine months of 2022. The company is facing escalation in fuel costs as oil prices move north is worrisome. Shares of Union Pacific have underperformed the Zacks Transportation - Rail industry over the past year (-10.5% vs. (You can read the full research report on Abbott Laboratories here >) Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship CGM system, FreeStyle Libre. However, excluding these negative factors, total worldwide sales increased 6% on an organic basis, benefitting from robust sales growth across the company’s core Established Pharmaceuticals and Medical Devices segments. The company’s sales were negatively impacted by COVID-19 testing-related sales decline and a manufacturing stoppage initiated in February of certain infant nutrition formula products manufactured at Abbott's Sturgis, MI, facility. (You can read the full research report on Pfizer here >)Ībbott Laboratories shares have declined -10.1% over the past year against the Zacks Medical - Products industry’s decline of -38.4%. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Its COVID-19 vaccine and oral antiviral pill for COVID-19, Paxlovid have become a key contributor to the top line. However, Pfizer boasts a diversified portfolio of innovative drugs and vaccines, including Ibrance and Prevnar. Pfizer has a mixed record of earnings surprises in the recent quarters. Other issues like currency headwinds and pricing pressures are some of the other concerns.Įstimates have gone down slightly ahead of Q4 earnings. +14.6%), with the absence of credible growth drivers beyond the company's Covid offerings as the primary drag. Shares of Pfizer have underperformed the Zacks Large Cap Pharmaceuticals industry over the past year (-13.9% vs. ![]() You can see all of today’s research reports here > These research reports have been hand-picked from the roughly 70 reports published by our analyst team today. (PFE), Abbott Laboratories (ABT) and Union Pacific Corporation (UNP). Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. The Zacks Research Daily presents the best research output of our analyst team.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |